Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Gemin X
- Target Recruit Count
- 24
- Registration Number
- NCT00407303
- Locations
- 🇺🇸
Roswell Park Medical Center, Buffalo, New York, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 307
- Registration Number
- NCT00401843
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 84
- Registration Number
- NCT00401011
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Sparrow Regional Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00389701
- Locations
- 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 27
- Registration Number
- NCT00389805
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 24
- Registration Number
- NCT00388089
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Pure Erythroid LeukemiaRecurrent Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Myelomonocytic LeukemiaRecurrent DiseaseAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal Differentiation
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00383474
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
- Conditions
- Stage III Childhood Hodgkin LymphomaStage IV Childhood Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaChildhood Mixed Cellularity Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaStage I Adult Hodgkin LymphomaStage I Childhood Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaChildhood Nodular Sclerosis Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00381940
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
- Conditions
- Interventions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT00379574
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷Asan Medical Cener, Seoul, Korea, Republic of
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 65
- Registration Number
- NCT00378209
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.